Benralizumab, marketed as Fasenra, has been approved by the US FDA for treating asthma in children aged 6 years and older with severe eosinophilic asthma. Originally approved in 2017 for patients aged 12 and older, the drug has shown consistent safety and tolerability in younger patients. AstraZeneca announced the expanded indication on April 11, with a recommended dose of 30 mg for children weighing 35 kg or more, and a new 10 mg dose for those weighing less. Benralizumab, a monoclonal antibody that targets eosinophils, is administered via subcutaneous injection every 4 weeks initially, and every 8 weeks thereafter. Common side effects include headache and pharyngitis, and the drug should not be used for acute asthma symptoms due to potential hypersensitivity reactions.
Source link
FDA Expands Benralizumab Use for Asthma to Kids Over Age 6
